RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 151 filers reported holding RA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 16.18 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $71,320,000 | +74.5% | 1,519,718 | -12.1% | 2.28% | +36.6% |
| Q3 2019 | $40,868,000 | -20.7% | 1,728,019 | +0.9% | 1.67% | -9.9% |
| Q2 2019 | $51,510,000 | +53.1% | 1,713,000 | +14.0% | 1.85% | +43.4% |
| Q1 2019 | $33,645,000 | +23.1% | 1,502,000 | 0.0% | 1.29% | +17.9% |
| Q4 2018 | $27,336,000 | +294.9% | 1,502,000 | +292.5% | 1.09% | +341.1% |
| Q3 2018 | $6,923,000 | +81.8% | 382,700 | 0.0% | 0.25% | +85.1% |
| Q2 2018 | $3,808,000 | +87.4% | 382,700 | 0.0% | 0.13% | +91.4% |
| Q1 2018 | $2,032,000 | +201.9% | 382,700 | +383.5% | 0.07% | +169.2% |
| Q4 2017 | $673,000 | -54.9% | 79,150 | -22.5% | 0.03% | -61.2% |
| Q3 2017 | $1,491,000 | -3.7% | 102,150 | +23.7% | 0.07% | -19.3% |
| Q2 2017 | $1,548,000 | -59.1% | 82,593 | -53.6% | 0.08% | -43.2% |
| Q1 2017 | $3,786,000 | -23.0% | 177,830 | -45.1% | 0.15% | -27.7% |
| Q4 2016 | $4,916,000 | – | 323,630 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $294,724,000 | 15.40% |
| RA Capital Management | 4,858,260 | $233,245,000 | 7.37% |
| HAVENS ADVISORS LLC | 143,266 | $6,878,000 | 6.70% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 609,614 | $29,267,000 | 6.40% |
| OMNI PARTNERS LLP | 1,052,744 | $50,542,000 | 4.45% |
| HBK INVESTMENTS L P | 2,004,042 | $96,214,000 | 4.03% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,005,600 | $96,289,000 | 3.83% |
| Versor Investments LP | 1,108,845 | $53,236,000 | 3.53% |
| OXFORD ASSET MANAGEMENT LLP | 461,016 | $22,133,000 | 3.12% |
| HighVista Strategies LLC | 63,222 | $3,035,000 | 2.81% |